AstraZeneca and Daiichi Sankyo have claimed ... datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after ...

AstraZeneca and Daiichi Sankyo’s antibody-drug ... or negative breast cancer in this and possibly earlier settings.” Dato-DXd has also generated promising results when used alongside Merck ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

But it's not all bad news. A PET scan of a female patient with breast cancer, which has spread to the lymph nodes, bones and liver. In its recent annual report, the American Cancer Society shared ...

AstraZeneca's metastatic breast cancer treatment gets EU recommendation SA News Fri, Feb. 28 Earnings Call Insights Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum ...